Attgeno AB is registered to facilitate the commercial development of the new concept for creating new NO donating compositions. 

Patent development is funded by own resources and in part by the company Aerocrine who receives the rights of Attgeno´s patent application for the diagnosis of pulmonary embolism. Attgeno wins the first prize in Karolinska Institute’s innovation competition.

Attgeno registered